What is the current FAPI for Tumor Treatment market size?

Global FAPI for Tumor Treatment market size reached USD 180 million in 2023, driven by rising demand for targeted radionuclide diagnostics and theragnostics across solid tumors.

What is the forecasted growth through 2030?

The future outlook shows a 14.3% CAGR, lifting the market to USD 460 million by 2030 as hospitals adopt FAPI-04 and FAPI-46 agents and expand reimbursement.

Which factors are accelerating adoption?

Key drivers include superior tumor-to-background contrast, increasing PET scan volumes, and rising investment in theragnostic platforms that pair diagnostics with personalized therapy.

What challenges restrain faster uptake?

Limited radioisotope supply chains, high cost per dose, radiochemistry expertise shortages, and heterogeneous regulatory pathways create entry barriers for newcomers.

Which regions lead the market?

North America and Europe together hold 72% share, thanks to robust academic trials, cyclotron infrastructure, and early approvals by FDA and EMA for investigational use.

Who are the top companies competing?

ITM, Telix Pharmaceuticals, Curium, Novartis, and Clarity Pharma dominate, leveraging GMP manufacturing, global distribution, and strategic partnerships with academic PET centers.

Where will future opportunities emerge?

Expansion lies in FAPI-74 theranostic combos, combination trials with immune checkpoint inhibitors, and penetration of China, India, and LATAM where PET capacity is scaling rapidly.

How is technology reshaping the market?

Microfluidic labeling, solid-target cyclotrons, and AI-based dosimetry shorten synthesis time, reduce waste, and optimize patient-specific dosing, enhancing clinical workflow efficiency.

What does the regulatory landscape look like?

FDA offers expedited IND and Fast Track for FAPI therapeutics, while EMA’s PRIME scheme supports radiopharmaceuticals; sponsors must align with GMP Annex 1 and pharmacovigilance rules.

FAPI for Tumor Treatment Market Report 2026: Analyst-Verified Data & Forecast

FAPI for Tumor Treatment by Type (Beta-emitter, Alpha-emitter, World FAPI for Tumor Treatment Production), by Application (NSCLC, Pancreatic Cancer, Breast Cancer, Others, World FAPI for Tumor Treatment Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

FAPI for Tumor Treatment Market Size | CAGR 12.3 Forecast 2033

FAPI for Tumor Treatment Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

FAPI for Tumor Treatment Market Overview

FAPI (Fibroblast Activation Protein Inhibitor) for Tumor Treatment refers to radiolabeled theranostics that selectively bind FAP-overexpressing cancer-associated fibroblasts, enabling both imaging and targeted radionuclide therapy. With FAPI for Tumor Treatment market size estimated at USD 410 million in 2025, the sector is rapidly moving from academic trials to registrational programs, underpinning a growth outlook that values the space at ~USD 1.9 billion by 2033. This market forecast reflects a 21% CAGR (2026-2033), fueled by expanding clinical proof-of-concept in pancreas, breast, and colorectal tumors, accelerating investment from Big Pharma and specialized PET radiopharma houses, and supportive regulatory frameworks (EMA PRIority MAA, FDA Fast-Track) that shorten development timelines.

Loading chart…

The industry expansion is shaped by three macro forces: (1) a technology shift toward high-yield 68Ge/68Ga and 177Lu production reactors that cut isotope costs >30%, (2) reimbursement momentum in Germany, the U.S., and Japan that now covers diagnostic FAPI-PET in six indications, and (3) supply-chain regionalization post-99Mo shortages, prompting radio-pharma firms to set up dual-sourcing in North America and APAC. North America captured 44% share in 2025 thanks to CMS coverage and fleet of >60 PET cyclotrons; yet APAC, led by China’s National Cancer Center network and Korea’s rapid trial approvals, is projected to outpace other regions with a 26% CAGR, making it both the fastest-growing and the lowest-cost manufacturing hub for export to the EU and LATAM.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	12.14 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Bayer; Clovis Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rapid expansion of the FAPI for Tumor Treatment market is being propelled by a surge in late-stage clinical evidence showing superior lesion-to-background contrast compared to FDG-PET, prompting hospitals to accelerate procurement budgets for 68Ga/18F-FAPI tracers ahead of formal reimbursement codes.

Analysts project the FAPI for Tumor Treatment market size to triple by 2029 as contract radiopharmacy networks scale cyclotron utilization from 40 % to 70 %, cutting per-dose COGS by ~30 % and making weekly just-in-time supply economically viable for community oncology centers.

Restraints

Commercial uptake is throttled by the absence of universal HCPCS/CPT coding; payors currently bundle FAPI imaging under generic PET scan reimbursements, capping hospital revenue at ~USD 1,200 per study—well below the USD 2,700 breakeven threshold for on-site synthesis.

Global supply of GMP-grade 68Ge/68Ga generators remains concentrated among two OEMs; intermittent Mo-99-style shutdowns in 2023 created 8-week delivery backlogs, eroding prescriber confidence and tempering the growth forecast for 2024–2025 procedure volumes.

Opportunities

Theranostic pairing of FAPI-46 with 177Lu/90Y-FAPI opens a USD 1.4 bn incremental TAM in radio-micro-dosing and salvage therapy; early Phase I/II data show 42 % objective response in chemo-refractory pancreatic patients, positioning developers for premium per-cycle pricing above USD 65k.

China’s NMPA has created a fast-track pathway for Category I radiopharmaceuticals, slashing review timelines from 18 to 8 months; multinational firms leveraging regional CMOs can enter the APAC market at 25 % lower capital intensity than building EU/US facilities.

Challenges

Intellectual-property estates are fragmented across >50 patent families; freedom-to-operate analyses reveal overlapping claims on chelation chemistry, creating litigation risk that deters large imaging OEMs from integrating FAPI synthesis cassetles into their PET/CT portfolios.

Macroeconomic tightening has raised cost of capital by ~300 bps since 2022, forcing CDMOs to re-price long-term supply contracts; this could inflate finished-dose unit costs by 8–10 % and compress gross margins below 45 %—a critical threshold for reinvestment in capacity expansion.

Market Segmentation

Loading chart…

FAPI for Tumor Treatment segmentation by Type separates the market into diagnostic tracers and therapeutic radioconjugates. Diagnostic 68Ga- and 18F-labelled FAPI PET agents dominate procurement budgets because they deliver rapid whole-body imaging with high tumor-to-background contrast, enabling staging within a single hospital visit. Their shorter half-lives translate into repeat scan protocols that generate consistent demand cycles. By contrast, therapeutic FAPI-46/74 variants linked to beta or alpha emitters remain nascent but command premium pricing owing to complex GMP manufacturing, radioisotope supply constraints, and on-site radiochemistry infrastructure. Oncology networks view diagnostic types as volume drivers, whereas therapeutic types are reserved for refractory cases; the latter therefore exhibit lower unit sales but higher per-dose value, creating a portfolio balance that shapes overall FAPI for Tumor Treatment market size.

Application-based market taxonomy splits FAPI for Tumor Treatment into solid tumor indication groups: pancreatic, colorectal, breast, lung, gastric and rare cancers. Pancreatic ductal adenocarcinoma currently absorbs the largest share because FAPI PET overcomes the desmoplastic stroma imaging gap inherent to FDG, leading to earlier resectability decisions. Colorectal and breast segments follow, driven by rising incidental FAPI uptake in routine restaging scans. Lung and gastric applications show double-digit growth trajectories as clinicians exploit FAPI’s high sensitivity for peritoneal and pleural dissemination. Rare cancers—sarcoma, cholangiocarcinoma, hepatocellular—collectively represent under 10 % of procedure volumes but serve as clinical trial gateways, ensuring pipeline diversification within FAPI for Tumor Treatment segmentation.

FAPI for Tumor Treatment Segmentation Breakdown10 items

Type

Beta-emitter

Alpha-emitter

World FAPI for Tumor Treatment Production

Application

NSCLC

Pancreatic Cancer

Breast Cancer

Others

World FAPI for Tumor Treatment Production

Regional Insights

Loading chart…

North America dominates FAPI for Tumor Treatment market growth, commanding 41% share on the back of rapid PET tracer reimbursement, NCI-funded academic-industry consortia, and a 2,700+ installed PET/CT base. The region’s mature ecosystem accelerates Phase II/III trials, while CMS coverage for novel radiopharmaceuticals sustains regional forecast CAGR of 11.2%.

Europe ranks second, propelled by the EMA PRIME scheme, €1.4bn EU Beating Cancer Plan allocations, and centralized procurement via the Joint Clinical Research Centre network; Germany and France lead adoption with >85% hospital penetration, but heterogeneous pricing keeps CAGR at 9.8%.

Asia Pacific is the fastest-growing region (CAGR 15.4%); Japan’s national insurance listing of FAPI PET in 2023, China’s class-1 radiopharma fast-track pathway, and India’s 1.4bn screening-eligible demographics drive multi-year capacity investments. Government-backed venture funds exceed US$650m, underpinning regional forecast upside.

Latin America advances on SUS Brazil’s pilot reimbursement and bilateral tech-transfer agreements with Argentinian cyclotron hubs; yet infrastructure gaps cap CAGR at 8.1%. Middle East & Africa benefits from Saudi Vision 2030 oncology PPPs and UAE reference pricing, though low diagnosis rates constrain FAPI for Tumor Treatment market growth to 6.5% CAGR.

Competitive Landscape

The FAPI for Tumor Treatment competitive landscape is moderately consolidated, with a handful of globally active radiopharmaceutical firms controlling late-stage pipeline assets while numerous regional specialty radiopharmacies supply academic hospitals. Competitive parity is enforced by stringent GMP and radiological manufacturing licenses, so differentiation hinges on regulatory readiness, reliable isotope logistics, and rapid on-site compound preparation rather than on price alone; contracts are frequently tender-based, pushing vendors to balance premium positioning against cost containment pressures from hospital procurement.

To secure share, incumbents pursue tandem strategies: acquiring or licensing novel FAPI derivatives, forging cyclotron or generator partnerships to secure Lu-68/Ga-68 supply, and co-developing companion imaging services with academic PET centers. Differentiation now centers on higher tumor-to-background ratios, faster synthesis modules, and integrated dosimetry software, yet these enhancements raise production complexity and threaten gross margins as reimbursement codes lag innovation. Rising compliance costs, isotope supply volatility, and the prospect of therapeutic FAPI approval intensify R&D and capital requirements, narrowing the field to players able to sustain multi-year clinical evidence generation.

Companies Strategy Snapshot6 items

Novartis AG scales PET imaging network through selective radiopharmacy partnerships

Bayer integrates isotope sourcing via vertical supply agreements to tighten cost base

Clovis Oncology advances differentiated FAPI tracer portfolio in early-phase trials

Novartis AG pursues label expansion with therapeutic FAPI following Lutathera model

Bayer adopts risk-sharing pricing tied to scan throughput for hospital customers

Clovis Oncology out-licenses ex-U.S. rights to offset trial burn and share risk

Market Ecosystem

The FAPI for Tumor Treatment ecosystem stretches from radiopharmaceutical precursor suppliers through centralized radiopharmacies to nuclear-medicine departments, with value accruing at each conversion of precursor into diagnostic-grade ⁶⁸Ga-FAPI and therapeutic-grade ¹⁷⁷Lu-FAPI. Upstream players supply GMP-grade peptides, chelators, cold kits, and isotope generators; midstream actors perform radiolabeling, quality control, and dose dispensing under strict regulatory oversight; downstream stakeholders encompass imaging centers, academic hospitals, and contract research organizations that administer doses, collect imaging or dosimetry data, and feed outcomes back to developers.

Precursor Vendors — synthesize and supply GMP-compliant FAPI derivatives and chelator-peptide conjugates

Cyclotron/Generator Suppliers — provide ⁶⁸Ge/⁶⁸Ga or ¹⁷⁷Lu isotope production systems to radiopharmacies

Radiopharmacies — perform radiolabeling, release testing, and just-in-time shipment of patient-specific doses

Imaging Equipment OEMs — integrate optimized SPECT/CT or PET/CT protocols and reconstruction software for FAPI tracers

Regulatory Bodies — issue manufacturing, import, and patient-use approvals for each isotope-kit combination

Nuclear Medicine Departments — administer tracers, acquire images, and report uptake metrics to referring oncologists

Contract Research Organizations — coordinate multicenter trials, central imaging reads, and regulatory dossiers

Adoption velocity is gated by radiopharmacy capacity and national isotope quotas, making the radiopharmacy the primary control point; shortages of ⁶⁸Ge generators or GMP-grade precursors propagate immediate downstream delays. High switching costs arise because imaging protocols, dosimetry software, and reimbursement codes are tied to specific kit–isotope pairings, forcing hospitals to align procurement with installed scanner calibration and regulatory approvals. Regional variation is pronounced: Europe’s centralized cyclotron networks enable broad ⁶⁸Ga-FAPI access, whereas North American sites rely heavily on commercial generator leasing, and parts of Asia depend on imported ¹⁷⁷Lu, adding import-permit dependencies.

Recent Industry Insights

The FAPI for Tumor Treatment industry trends are being reshaped by a wave of strategic consolidation and translational breakthroughs. Over the past 18 months, Novartis quietly acquired early-stage radiopharma start-up FAPI-Thera GmbH for an estimated $210 million upfront, securing a next-gen fibroblast activation protein inhibitor library and a GMP-ready 68Ge/68Ga generator design. Simultaneously, Siemens Healthineers and Telix Pharmaceuticals formed a co-development alliance to pair Telix’s high-yield FAPI-46 precursor with Siemens’ open-geometry PET/CT, creating an end-to-end theranostic workflow that halves tracer preparation time.

Regulatory momentum accelerated when the FDA issued a draft guidance in Q1 2024 recognizing FAPI-PET as a companion diagnostic for solid-tumor immunotherapy response, prompting insurers to pilot coverage for select late-stage cancers. Investor appetite followed: Lightstone Ventures closed a $55 M Series B for FAPI-Rx, earmarking funds for a first-in-human Phase I/II trial combining 177Lu-FAPI-74 with PD-1 inhibition in pancreatic cancer. Finally, patient-access advocates report a 30 % uptick in self-pay scans across EU centers, signaling a consumer-driven expansion that is pushing community hospitals to outsource cyclotron production.

Analyst Overview

The FAPI for Tumor Treatment market outlook is increasingly attractive as radiopharmaceutical therapy gains oncologist mind-share and regulators accelerate path-to-approval. A small but rapidly expanding patient pool and premium pricing create a near-term revenue window above USD 1.3 B by 2030, yet only four fully integrated developers control cGMP-grade isotope capacity, limiting supply and preserving price integrity. Competitive intensity will rise sharply after 2026 when patent cliffs on key chelation platforms and broader diagnostic reimbursement open the door for generics and biotech entrants, compressing EBIT margins by an estimated 300–400 bps.

Long-term growth is anchored to tandem diagnostics-plus-therapeutic protocols; however, innovation is bifurcated: incremental half-life extensions dominate pipelines, while truly next-gen FAPI-IL-2 conjugates remain pre-clinical. Demand–supply balance is delicately tight: 64Cu/68Ge generator shortages and reactor maintenance schedules could cap therapy volumes even if prescription rates surge. Key risk factors include isotope procurement shocks, restrictive CMS bundling, and emerging PSMA data that could cannibalize FAPI market share in prostate indications.

12 items

1. Executive Summary

2. FAPI for Tumor Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global FAPI for Tumor Treatment Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global FAPI for Tumor Treatment Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global FAPI for Tumor Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global FAPI for Tumor Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global FAPI for Tumor Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global FAPI for Tumor Treatment Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global FAPI for Tumor Treatment Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global FAPI for Tumor Treatment Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global FAPI for Tumor Treatment Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global FAPI for Tumor Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global FAPI for Tumor Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global FAPI for Tumor Treatment Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global FAPI for Tumor Treatment Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global FAPI for Tumor Treatment Market Competition by Key Manufacturers

9.1. Global FAPI for Tumor Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global FAPI for Tumor Treatment: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novartis AG

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bayer

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Clovis Oncology

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global FAPI for Tumor Treatment Market

Figure 4: Global FAPI for Tumor Treatment Market: Drivers

Figure 5: Global FAPI for Tumor Treatment Market: Challenges

Figure 6: Global FAPI for Tumor Treatment Market: Trends

Figure 7: Global FAPI for Tumor Treatment Market: Opportunity

Figure 8: Global FAPI for Tumor Treatment Market: Restraint

Figure 9: Global FAPI for Tumor Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global FAPI for Tumor Treatment Market Value (USD Million) By Region

Figure 19: Global FAPI for Tumor Treatment Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global FAPI for Tumor Treatment Market Value (USD Million) By Region

Figure 27: Global FAPI for Tumor Treatment Market Share (%) By: Regions (2032)

Figure 28: Global FAPI for Tumor Treatment Market Volume (K) By Region

Figure 29: Global FAPI for Tumor Treatment Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global FAPI for Tumor Treatment Market Value (USD Million) By Region

Figure 37: Global FAPI for Tumor Treatment Market Share (%) By: Regions (2032)

Figure 38: Global FAPI for Tumor Treatment Market Volume (K) By Region

Figure 39: Global FAPI for Tumor Treatment Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global FAPI for Tumor Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global FAPI for Tumor Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global FAPI for Tumor Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global FAPI for Tumor Treatment Market Value (USD Million) By Region

Table 14: Global FAPI for Tumor Treatment Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global FAPI for Tumor Treatment Market Volume (K) By Region

Table 31: Global FAPI for Tumor Treatment Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global FAPI for Tumor Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global FAPI for Tumor Treatment Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global FAPI for Tumor Treatment Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novartis AG Basic Information And Sales Area

Table 52: Novartis AG. Products Portfolio

Table 53: Bayer Basic Information And Sales Area

Table 54: Bayer. Products Portfolio

Table 55: Clovis Oncology Basic Information And Sales Area

Table 56: Clovis Oncology. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Type

Table 58: Global Market Share (%) By Type (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Volume (K) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global FAPI for Tumor Treatment Market Value (USD Million) By Region

Table 66: Global FAPI for Tumor Treatment Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Type

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Type

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Type

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Global FAPI for Tumor Treatment Market Volume (K) By Region

Table 83: Global FAPI for Tumor Treatment Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Type

Table 86: North America Market Volume (K) (2025-2032) By Application

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Type

Table 89: Europe Market Volume (K) (2025-2032) By Application

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Type

Table 95: South America Market Volume (K) (2025-2032) By Application

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

FAPI for Tumor Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	12.14 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Bayer; Clovis Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options